**Name of Journal:** ***World Journal of Gastroenterology***

**Manuscript NO: 40712**

**Manuscript Type:** **EDITORIAL**

**Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges**

Piñero F *et al.* Challenges of HCC in Latin America

Federico Piñero, Jaime Poniachik, Ezequiel Ridruejo, Marcelo Silva

**Federico Piñero, Ezequiel Ridruejo, Marcelo Silva,** Liver Unit, Hospital Universitario Austral, Facultad de Ciencias Biomédicas, Universidad Austral, Pilar, Buenos Aires B1629HJ, Argentina

**Federico Piñero,** **Ezequiel Ridruejo, Marcelo Silva,** Latin American Liver Research Educational and Awareness Network, Buenos Aires B1629HJ, Argentina

**Jaime Poniachik,** Department of Gastroenterology and Hepatology, Hospital Clínico Universidad de Chile, Santiago de Chile, Región Metropolitana Santiago 46010, Chile

**Jaime Poniachik,** Gastroenterology and Hepatology, Clínica Santa María, Santiago de Chile, Región Metropolitana Santiago 834-0518, Chile

**Ezequiel Ridruejo,** Hepatology Section, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Ciudad de Buenos Aires C1425ASG, Argentina

**ORCID number:** Federico Piñero (0000-0002-9528-2279); Jaime Poniachik (0000-0001-7958-3357); Ezequiel Ridruejo (0000-0002-3321-0683); Marcelo Silva (0000-0002-2287-7351).

**Author contributions:** Piñero F and Poniachik J contributed to concept and writing of the article; Ridruejo E and Silva M contributed to critical review and final approval of the article.

**Conflict-of-interest statement:** The authors of this manuscript have no conflicts of interest to declare.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** **Federico Piñero, MD, MSCE, Academic Research, Doctor,** Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Av. Presidente Perón 1500, Pilar, Buenos Aires B1629HJ, Argentina. fpinerof[@cas.austral.edu.ar](mailto:msilva@cas.austral.edu.ar)

**Telephone:** +54-230-4482000

**Fax:** +54-230-4482236

**Received:** July 5, 2018

**Peer-review started:** July 5, 2018

**First decision:** August 1, 2018

**Revised:** August 2, 2018

**Accepted:** August 24, 2018

**Article in press:**

**Published online:**

**Abstract**

Latin America, a region with a population greater than 600000000 individuals, is well known due to its wide geographic, socio-cultural and economic heterogeneity. Access to health care remains as the main barrier that challenges routine screening, early diagnosis and proper treatment of hepatocellular carcinoma (HCC). Therefore, identification of population at risk, implementation of surveillance programs and access to curative treatments has been poorly obtained in the region. Different retrospective cohort studies from the region have shown flaws in the implementation process of routine surveillance and early HCC diagnosis. Furthermore, adherence to clinical practice guidelines recommendations assessed in two studies from Brazil and Argentina demonstrated that there is also room for improvement in this field, similarly than the one observed in Europe and the United States. In summary, Latin America shares difficulties in HCC decision-making processes similar to those from developed countries. However, a transversal limitation in the region is the poor access to health care with the consequent limitation to standard treatments for overall population. Specifically, universal health care access to the different World Health Organization (WHO) levels is crucial, including improvement in research, education and continuous medical training in order to expand knowledge and generation of data promoting a continuous improvement in the care of HCC patients.

**Key words:** Latin America; Liver cancer; Limitations; Challenge

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Which are the implications in regard to clinical decision making processes related to hepatocellular carcinoma (HCC) in daily practice in Latin America? Should we consider making these decisions taking into account both, local experiences and their feasibility together with the best available evidence in parallel with patient preferences? These decision-making processes must be individualized according to local barriers to health care systems. Primary prevention programs of liver diseases, surveillance for HCC and intervention programs following the best evidence will be possible only if we are aware of local barriers and develop efficient strategies to overcome them.

Piñero F, Poniachik J, Ridruejo E, Silva M.Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges.*World J Gastroenterol* 2018; In press

**INTRODUCTION**

Latin American comprises a region of the Americas of Latin origin, in which the most common speaking languages are Spanish and Portuguese. The region accounts for more than twenty million square kilometers of surface area, with more than six hundred million population. Due to its geographic extension, Latin America has a great socio-cultural heterogeneity and an important socio-economic difference among countries. While there are high earners like Chile and Uruguay with a Gross Domestic Product (GDP) per capita over $ 20000, others like Haiti and Honduras have GDPs per capita lower than $ 5000[1]. At the same time, each country in itself is highly unequal, presenting some of the highest Globalization of Inequality (GINI) scores in the world. Brazil, Chile, Ecuador and Colombia all present GINIs above 0.45 for the year 2016; Argentina and Uruguay having slightly better scores[1]. In comparison, Sweden, Norway, Netherlands and Denmark all have GINI scores less than 0.30[1].

It is in this socio-cultural and economic scenario, where settles a large variety in access to health care systems in the region. These systems are mainly made up of a common payer and provider that is the state. However, in several countries, there are other type of health providers through social security and private insurances and providers. Furthermore, expenditure on access care in many Latin American countries comes from out-of-pocket money among high to middle income people. On the other hand, among low socio-economic classes, expenditure comes purely and exclusively from public services, which in most of the cases provide with low to regular quality of medical care services and shortage of appropriate medical supplies and devices.

**WHERE DO WE STAND IN LATIN AMERICA** **REGARDING HEPATOCELLULAR CARCINOMA?**

Hepatocellular carcinoma (HCC) is the second leading cause of cancer related death worldwide and the main cause of cancer in patients with cirrhosis. Incidence of hepatocellular carcinoma varies according to geographic location, depending on the prevalence of viral hepatitis among the world. The predominant reported causes of HCC in different geographic areas around the world have been related with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV) infection and alcoholic liver disease[2-5]. Heterogeneous data regarding epidemiology of HCC in Latin America has been reported

[6-12]. While HCV and alcoholic liver disease are the most frequent etiologies of HCC in the region, HBV is a leading cause in some countries, mainly in Brazil. More recently, we have observed a changing epidemiological trend of HCC towards an increasing non-alcoholic fatty liver disease, becoming an important public health burden in the region

[6,7].

As previously proposed by the World Health Organization (WHO) the structural challenge in the region is the uneven access to health care. To our knowledge there is not even one country with an integrated program to assist on the prevention of chronic liver diseases and early identification of the population at risk for developing HCC. Consequently, the common challenge for scientific societies is to induce regional policy makers to develop interventions and strategies able to identify the population at risk, implement surveillance programs, and improve access to curative and palliative treatments. Once we have assured access to adequate care we should move into next step which is the correct adherence to recommendations from clinical practice guidelines[2-5].

***A clinical case scenario as an example of where do we fail in Latin America***

The following clinical case demonstrates the regional shortcomings related to HCC diagnosis at late stages and its therapeutic consequences. A 60-year-old male patient with compensated cirrhosis and clinically significant portal hypertension due to chronic HCV infection, who started antiviral treatment with direct-acting antiviral agents, began an erratic path of ultrasound (US) screening for HCC. Surveillance was performed by non-liver expert sonographers due to insurance’s related lack of access to academic sites. Initially a 24-mm nodule was visualized and he was recommended to stay on a follow-up visit with no further imaging evaluation. Twelve months later, another US was performed; this time the nodule grew to 38 mm. He performed an abdominal computed tomography (CT) scan with oral contrast only, and the finding of an "uncharacteristic" nodule leaded to a CT-guided biopsy. The pathologic report was "nodules of hepatocellular regeneration separated by broad fibrous septa, cirrhosis". Result: no cancer. His physician suggested him to continue life normally and the patient happily went home.

A year later, a liver specialist suggested him to perform an abdominal CT scan with intravenous contrast. A heterogeneous 80-mm diameter lesion in the right hepatic lobe with “non-characteristic findings” was observed. Not satisfied, the patient looked for a second opinion. A second hepatologist performed a three-phase dynamic abdominal magnetic resonance imaging (MRI). Result: one lesion with arterial enhancement and wash out during portal and late phases: HCC of 83 mm, without vascular invasion. Serum alpha-fetoprotein value was 1200 ng/mL.

In the end, the patient consulted at least 4 medical doctors during a 2-year period, with extended and inadmissible delay in HCC diagnosis that at this point will probably exclude him from potentially curative treatments. Where did we fail?

***Early diagnosis of HCC: Challenges and areas of improvement***

This case, clearly illustrates some of the reasons for failure in routine surveillance and HCC diagnosis at early stages in Latin America, and as a consequence, failure in the appropriate staging and selection of therapies.

Screening failure entails three important points to be considered. First, absence of early identification of the population at risk, such as chronic HBV or HCV. Second, ineffective application of routine surveillance (semi-annual ultrasound performed by expert operators) and third, errors in interpretation of a positive or negative screening tests, misinterpreting its sensitivity and specificity.

Surveillance for HCC in Latin America demands a continuous improvement. Different retrospective cohort studies have shown flaws in the implementation process of routine surveillance, the consequent failure in the diagnosis in early stages and finally a notorious negative impact upon patient survival

[8-12] (Table 1).

Overall, surveillance programs reported to be applied in less than 50% of the patients in Latin America. This number perhaps does not show the "real" regional situation, since most of this data came from academic rather than general hospitals. Consequently, screening failure for HCC in this region might be even greater, demanding strategies to improve its implementation such as application of US done by experts, correct interpretation of imaging tests and finally, adequacy of therapeutic decisions according to the best evidence-based-medicine. Consequently, early HCC diagnosis should be the aim of these strategies.

As exemplified in the clinical case, the misuse of diagnostic tools delays the correct diagnosis. HCC diagnosis implies an appropriate oncologic imaging paradigm, not requiring histological confirmation for diagnosis in most of the cases. However, discordance between images and histology may occur. This situation has been reported up to 10% in Argentina when comparing imaging reports and explanted liver data from liver transplanted patients[13,14]. In a multicenter Latin American cohort study, false positives cases were less than 3%

[15]. Two different situations need to be further clarified when discussing imaging accuracy against histological confirmation of HCC. On one hand, when false positives are considered, it should be important to address if complete necrotic nodules were included as false positive cases resulting in a biased report. On the other hand, discrepancy between images and explanted liver should be considered taking into account potential tumor progression, and locoregional response to treatments during the waiting list period.

Nevertheless this led to changes in diagnostic criteria for HCC in patients enrolled for liver transplantation in Argentina aimed to improve imaging diagnostic accuracy. Although the idea was novel, LIRADS criteria implementation leaded even to a greater uncertainty for those cases where HCC diagnosis is probable or possible (LIRADS 3 or 4). Moreover, imaging expert’s agreement on LIRADS in the daily practice has been not assessed at all. Thus, LIRADS system seemed to make the clinical decision making process even more complex in daily practice in that country[16,17].

***Challenges regarding staging and adherence to recommended treatment options from clinical practice guidelines***

HCC staging considering the Barcelona Clinic Liver Cancer (BCLC) algorithm has been recommended in different clinical practice guidelines[3,4], including that from the Latin American Association for the Study of the Liver (ALEH)[3]. However, strict adherence to these therapeutic recommendations is often not feasible in daily practice. This does not contradict the BCLC algorithm, since its explicitly recommends that the therapeutic choice must be individualized considering feasibility, access and preferences of the patients[18]. In addition, there are different guidelines and recommendations, including those from Asia (APASL)[5], Japan and South Korea. Consequently, there is a wide range of treatment algorithms when considering HCC.

The BRIDGE study demonstrated the great heterogeneity in terms of the treatments performed worldwide at each stage and far from that recommended in the ideal situation

[19]. Global and individual context makes therapeutic decisions in HCC heterogeneous in real life. Adherence to clinical practice guidelines recommendations varies between 40%-70% in different retrospective cohort studies

[20-26]. Two Latin American studies evaluated adherence to BCLC and its impact on survival. In a study from Brazil, adherence to BCLC did not have a favorable impact on survival[25]. However, there was a selection bias when "non-adherence" was categorized in those patients within BCLC-D stage who were candidates for liver transplantation. Precisely, the BCLC clarifies in its footnote that these patients must be transplanted. In a dual cohort study in Argentina, adherence to BCLC was greater than 50%, being associated with better overall survival[26] (Table 2).

In summary, although Latin America shares some difficulties in HCC decision-making processes similar to those reported in some developed countries, we still have big gaps when compared to them. These gaps are seen in medical education, on early and accurate HCC diagnosis, and in universal access to good diagnostic technology and to curative treatments. Until they are corrected, discrepancy on HCC related survival would remain present.

**PERSPECTIVE**

Consequently, we shall make decisions considering local education, expertise and feasibility together with the best available evidence. Ultimately, this decision-making-process must be individualized[27].

Which are the areas for improvement in Latin America? Specifically, universal health care access as per World Health Organization (WHO) recommendation is crucial. This includes improvement in transmission of information and medical education from academic to primary health care centers, focusing on prevention of development of liver diseases, identification of population at risk for HCC, systematic implementation of routine surveillance programs, improvement in the diagnostic work-up process and finally, promoting overall access to all treatments strategies which have shown improvement in patient´s survival (Figure 1). Finally, an important field to promote in the region is the development of research consortia such as the Latin American Liver Research Educational and Awareness Network (LALREAN), through which we can multiply medical education and generation of regional data necessary to develop efficient health interventions for improvement the care of patients with HCC[28].

**REFERENCES**

1 **World Bank.** International Comparison Program database. Available from: URL: <https://data.worldbank.org>

2 **Heimbach JK**, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology* 2018; **67**: 358-380 [PMID: 28130846 DOI: 10.1002/hep.29086]

3 **Méndez-Sánchez N,** Ridruejo E, Alves de Mattos A, Chávez-Tapia NC, Zapata R, Paraná R, Mastai R, Strauss E, Guevara-Casallas LG, Daruich J, Gadano A, Parise ER, Uribe M, Aguilar-Olivos NE, Dagher L, Ferraz-Neto BH, Valdés-Sánchez M, Sánchez-Avila JF. Latin American Association for the Study of the Liver clinical practice guidelines: management of hepatocellular carcinoma. Annals of Hepatology 2014;**13** Suppl 1: S4–S40 [PMID 24998696]

4 **European Association for the Study of the Liver.** European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018; **69**: 182-236 [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019]

5 **Omata M**, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int* 2017; **11**: 317-370 [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9]

6 **Piñero F**, Pages J, Marciano S, Fernández N, Silva J, Anders M, Zerega A, Ridruejo E, Ameigeiras B, D'Amico C, Gaite L, Bermúdez C, Cobos M, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Silva M. Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina. *World J Hepatol* 2018; **10**: 41-50 [PMID: 29399277 DOI: 10.4254/wjh.v10.i1.41]

7 **Piñero F**, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Padilla Machaca M, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Maraschio M, Podestá LG, McCormack L, Gadano A, Boin ISFF, García P, Silva M; Latin American Liver Research, Education, Awareness Network (LALREAN). A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America. *Clin Res Hepatol Gastroenterol* 2018; Epub ahead of print [PMID: 29773419 DOI: 10.1016/j.clinre.2018.03.014]

8 **Fassio E**, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L; Multicenter Group for Study of Hepatocarcinoma in Latin America; Asociación Latinoamericana para el Estudio del Hígado (ALEH). Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. *Ann Hepatol* 2010; **9**: 63-69 [PMID: 20332549]

9 **Paranaguá-Vezozzo DC**, Ono SK, Alvarado-Mora MV, Farias AQ, Cunha-Silva M, França JI, Alves VA, Sherman M, Carrilho FJ. Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort. *Ann Hepatol* 2014; **13**: 386-393 [PMID: 24927609]

10 **Piñero F**, Marciano S, Anders M, Orozco F, Zerega A, Cabrera CR, Baña MT, Gil O, Andriani O, de Santibañes E, McCormack L, Gadano A, Silva M. Screening for liver cancer during transplant waiting list: a multicenter study from South America. *Eur J Gastroenterol Hepatol* 2015; **27**: 355-360 [PMID: 25563142 DOI: 10.1097/MEG.0000000000000272]

11 **Appel-da-Silva MC**, Miozzo SA, Dossin IA, Tovo CV, Branco F, de Mattos AA. Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study. *World J Gastroenterol* 2016; **22**: 10219-10225 [PMID: 28028370 DOI: 10.3748/wjg.v22.i46.10219]

12 **Debes JD**, Chan AJ, Balderramo D, Kikuchi L, Gonzalez Ballerga E, Prieto JE, Tapias M, Idrovo V, Davalos MB, Cairo F, Barreyro FJ, Paredes S, Hernandez N, Avendaño K, Diaz Ferrer J, Yang JD, Carrera E, Garcia JA, Mattos AZ, Hirsch BS, Gonçalves PT, Carrilho FJ, Roberts LR. Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. *Liver Int* 2018; **38**: 136-143 [PMID: 28640517 DOI: 10.1111/liv.13502]

13 **McCormack L**, Gadano A, Lendoire J, Imventarza O, Andriani O, Gil O, Toselli L, Bisigniano L, de Santibañes E. Model for end-stage liver disease-based allocation system for liver transplantation in Argentina: does it work outside the United States? *HPB (Oxford)* 2010; **12**: 456-464 [PMID: 20815854 DOI: 10.1111/j.1477-2574.2010.00199.x]

14 **Cejas NG**, Villamil FG, Lendoire JC, Tagliafichi V, Lopez A, Krogh DH, Soratti CA, Bisigniano L. Improved waiting-list outcomes in Argentina after the adoption of a model for end-stage liver disease-based liver allocation policy. *Liver Transpl* 2013; **19**: 711-720 [PMID: 23775946 DOI: 10.1002/lt.23665]

15 **Piñero F**, Tisi Baña M, de Ataide EC, Hoyos Duque S, Marciano S, Varón A, Anders M, Zerega A, Menéndez J, Zapata R, Muñoz L, Padilla Machaca M, Soza A, McCormack L, Poniachik J, Podestá LG, Gadano A, Boin IS, Duvoux C, Silva M; Latin American Liver Research, Education and Awareness Network (LALREAN). Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America. *Liver Int* 2016; **36**: 1657-1667 [PMID: 27169841 DOI: 10.1111/liv.13159]

16 **Ayuso C**, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, Bianchi L, Belmonte E, Caparroz C, Barrufet M, Bruix J, Brú C. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. *Eur J Radiol* 2018; **101**: 72-81 [PMID: 29571804 DOI: 10.1016/j.ejrad.2018.01.025]

17 **Mitchell DG**, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. *Hepatology* 2015; **61**: 1056-1065 [PMID: 25041904 DOI: 10.1002/hep.27304]

18 **Forner A**, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet* 2018; **391**: 1301-1314 [PMID: 29307467 DOI: 10.1016/S0140-6736(18)30010-2]

19 **Park JW**, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. *Liver Int* 2015; **35**: 2155-2166 [PMID: 25752327 DOI: 10.1111/liv.12818]

20 **Leoni S**, Piscaglia F, Serio I, Terzi E, Pettinari I, Croci L, Marinelli S, Benevento F, Golfieri R, Bolondi L. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. *Dig Liver Dis* 2014; **46**: 549-555 [PMID: 24630947 DOI: 10.1016/j.dld.2014.02.012]

21 **Gashin L**, Tapper E, Babalola A, Lai KC, Miksad R, Malik R, Cohen E. Determinants and outcomes of adherence to recommendations from a multidisciplinary tumour conference for hepatocellular carcinoma. *HPB (Oxford)* 2014; **16**: 1009-1015 [PMID: 24888730 DOI: 10.1111/hpb.12280]

22 **Kim KM**, Sinn DH, Jung SH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients? *Liver Int* 2016; **36**: 1490-1497 [PMID: 26936471 DOI: 10.1111/liv.13107]

23 **Wallace MC**, Huang Y, Preen DB, Garas G, Adams LA, MacQuillan G, Tibballs J, Ferguson J, Samuelson S, Jeffrey GP. HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival. *Dig Dis Sci* 2017; **62**: 2182-2192 [PMID: 28547649 DOI: 10.1007/s10620-017-4622-y]

24 **Guarino M**, Tortora R, de Stefano G, Coppola C, Morisco F, Salomone Megna A, Izzo F, Nardone G, Piai G, Adinolfi LE, D'Adamo G, Gaeta GB, Messina V, Francica G, De Girolamo V, Coppola N, Persico M, Di Costanzo GG; Progetto Epatocarcinoma Campania Group. Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. *J Gastroenterol Hepatol* 2018; **33**: 1123-1130 [PMID: 28994145 DOI: 10.1111/jgh.14013]

25 **Kikuchi L**, Chagas AL, Alencar RSSM, Tani C, Diniz MA, D'Albuquerque LAC, Carrilho FJ. Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage. *Clinics (Sao Paulo)* 2017; **72**: 454-460 [PMID: 28954003 DOI: 10.6061/clinics/2017(08)01]

26 **Piñero F**, Marciano S, Fernández N, Silva J, Zambelo Y, Cobos M, Zerega A, Ridruejo E, Miguez C, Ameigeiras B, D'Amico C, Gaite L, Coronel M, Bermúdez C, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Rubinstein F, Silva M; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina. *Eur J Gastroenterol Hepatol* 2018; **30**: 376-383 [PMID: 29509603 DOI: 10.1097/MEG.0000000000001049]

27 **Bruix J**, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. *Gastroenterology* 2016; **150**: 835-853 [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041]

28 **Mendizabal M**, Silva MO. Developing multicenter consortia in liver disease in Latin America: Challenges and opportunities. *Liver Transpl* 2017; **23**: 1210-1215 [PMID: 28590520 DOI: 10.1002/lt.24793]

**P-Reviewer:** Jang BK, Marcos M

**S-Editor:** Ma RY **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Argentina

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Areas of improvement regarding hepatocellular carcinoma in Latin America.**

**Table 1** **Surveillance for hepatocellular carcinoma in Latin America**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study** | **Population** | **Design** | **Results** |
| Fassio E *et al*  [8] | *n* = 240 HCC  Brazil, Arg, Colombia, Chile, Uruguay, Venezuela | Prospective cohort  (Surveillance retrospectively analyzed) | 54% under surveillance  BCLC A 70% *vs* 39% not under surveillance  No survival analysis |
| Paranaguá-Vezozzo D *et al*  [9] | *n* = 884  Cirrhosis Child A-B  Brazil, Sao Paulo | Retrospective cohort  US +/- AFP annual | HCC annual incidence 2.9%  75% under annual surveillance  80% within Milan, better survival |
| Piñero F *et al*  [10] | *n* = 643  Cirrhosis, waiting list for liver transplantation.  Argentina | Retrospective cohort  Surveillance Failure = incidental HCC in the explant | US accuracy:  S 33% y E 99% |
| Campos Appel-da-Silva M *et al*  [11] | n=453  Child A-C Cirrhosis  Brazil, Porto Alegre | Retrospective cohort  US +/- AFP every 6 mo | 50.7% under surveillance  More BCLC 0-A *vs* no screening  Better survival within Milan criteria |
| Debes J *et al*  [12] | *n* = 1336  HCC  Brazil, Argentina, Colombia, Peru, Uruguay, Ecuador | Retrospective cohort | 47% under surveillance  Better survival *vs* symptomatic diagnosis  (adjusted for lead-time bias) |

BCLC: Barcelona Clinic Liver Cancer; HCC: Hepatocellular carcinoma; US: Ultrasound.

**Table 2 Adherence to clinical practice guidelines around the world and in Latin America**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study** | **Population** | **Design** | **Results** |
| Leoni S *et al*  [20] | *n* = 227  HCV 58% Child A 54% | Retrospective cohort  (2005-2010)  One center | At HCC diagnosis:  BCLC 0-A 55%  Adherence to BCLC 60%  Higher adherence among BCLC A 86% |
| Gashin L *et al*  [21] | *n* = 137  HCV 62% | Retrospective cohort  (2009-2010)  One center | Adherence to BCLC 62%  Better overall survival  Heterogeneous causes of non-adherence |
| Kim KM *et al*  [22] | *n* = 3515  HBV 77% Child A 82% | Retrospective cohort  (2005-2009)  One center | At HCC diagnosis:  BCLC A 59%  Adherence to BCLC 49%  Better survival for adherence, except BCLC-D  (BCLC D who were transplanted were considered  “non-adherence”) |
| Wallace M  [23] | *n* = 292  OH-HCV 65% | Retrospective cohort  (2006-2014)  One center | At HCC diagnosis:  BCLC 0-A 64%  Adherence to BCLC 48% *vs*  HKLC 56% (P.001)  No better survival among BCLC adherence *vs* no-adherence but better survival among HKLC  (TACE before transplant was considered “no-adherence”) |
| Guarino M *et al*  [24] | *n* = 1008  HCV  Child A 73% | Retrospective cohort  (2013-2015)  Multicenter study | At HCC diagnosis: BCLC 0-A 59%  Adherence BCLC 71%, lower in BCLC B 36% and C 46%  No better survival  (TACE before transplant was considered “no-adherence”) |
| Kikuchi L *et al*  [25] | *n* = 364  HBV 53% Child A 53% | Retrospective cohort  (2010-2012)  One center | At HCC diagnosis: BCLC A 36%  Adherence BCLC 52%  Lower adherence in BCLC C-D  No better survival, except in BCLC A  (BCLC D who were transplanted were considered  “non-adherence”) |
| Piñero F *et al*  [26] | *n* = 708  HCV 58% Child A 54% | Dual cohort  (2009-2016)  Multicenter study | At HCC diagnosis: BCLC 0-A 47%  Adherence BCLC 53% initial,  63% subsequently  Adherence to BCLC: better survival HR 0.67 (CI: 0.52-0.87) |

BCLC: Barcelona Clinic Liver Cancer; HKLC: Hong Kong Liver Cancer algorithm; HCV: Hepatitis C virus; HBV: Hepatitis B virus; TACE: Transarterial chemoembolization.